Pacira BioSciences stock set to leave S&P SmallCap 600
Published on 11/12/2026 at 03:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSIndex change and takeover status
- Pacira BioSciences is scheduled to leave the S&P SmallCap 600 before trading opens on November 17.
- Viatris is acquiring Pacira, with final closing conditions still pending.
- Ingram Micro is set to join the index in Pacira's place.
Pacira BioSciences stock is set to leave the S&P SmallCap 600 before trading opens on Tuesday, November 17. S&P Dow Jones Indices said on November 11 that Ingram Micro Holding will replace Pacira in the index as Viatris' acquisition moves toward closing, subject to final conditions.
Pacira BioSciences stock traded at 32.90 euros on Lang & Schwarz at 23:00 CET on Wednesday, November 11, 2026.
Takeover remains the central catalyst
The index change reflects the pending transaction rather than a new operating announcement from Pacira. Viatris has agreed to acquire the company, and the transaction is expected to close soon once the remaining closing conditions are satisfied.
The scheduled removal changes Pacira's representation in the small-cap benchmark ahead of the proposed deal completion. For investors, the key near-term issue remains the transaction timetable and whether the cash acquisition proceeds on its announced terms.
Pacira BioSciences at a glance
- Company: Pacira BioSciences, Inc.
- ISIN: US6951271005
- Ticker: PCRX
- Trading venue: Lang & Schwarz
- Price: 32.90 euros at 23:00 CET on November 11, 2026
Pacira BioSciences develops non-opioid pain therapies and focuses on targeted, locally administered treatments. Its investor materials identify two commercial-stage non-opioid treatments and a gene therapy asset aimed at prevalent diseases including osteoarthritis. The company is based in the United States and is transitioning toward ownership by Viatris under the announced acquisition.
The broader US equity market can be followed through the S&P 500 market overview.
